Cargando…

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

BRD4 is a transcriptional co-activator functioning to recruit regulatory complexes to acetylated chromatin. A subset of High-grade Serous Ovarian Cancer (HGSOC) patients are typified by focal, recurrent BRD4 gene amplifications. Despite previously described cancer dependencies, it is unclear whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhyasen, Garrett W., Yao, Yi, Zhang, Jingwen, Dulak, Austin, Castriotta, Lillian, Jacques, Kelly, Zhao, Wei, Gharahdaghi, Farzin, Hattersley, Maureen M., Lyne, Paul D., Clark, Edwin, Zinda, Michael, Fawell, Stephen E., Mills, Gordon B., Chen, Huawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056044/ https://www.ncbi.nlm.nih.gov/pubmed/30036377 http://dx.doi.org/10.1371/journal.pone.0200826

Ejemplares similares

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
por: Roberts, Thomas C., et al.
Publicado: (2017)

BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell
por: Deeney, Jude T., et al.
Publicado: (2016)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
por: Cribbs, Adam P., et al.
Publicado: (2021)

BRD4: A BET(ter) target for the treatment of AML?
por: Valent, Peter, et al.
Publicado: (2014)

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
por: Korb, Erica, et al.
Publicado: (2015)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4
por: Ahmed, Nasiha S., et al.
Publicado: (2021)

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
por: Petersen, Shariska, et al.
Publicado: (2020)

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
por: Zengerle, Michael, et al.
Publicado: (2015)

The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
por: Benito, E, et al.
Publicado: (2017)

Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4
por: Calder, Jack, et al.
Publicado: (2021)

Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins
por: Malvezzi, Francesca, et al.
Publicado: (2021)

Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2023)

Zebrafish brd2a and brd2b are paralogous members of the bromodomain-ET (BET) family of transcriptional coregulators that show structural and expression divergence
por: DiBenedetto, Angela J, et al.
Publicado: (2008)

Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
por: Bolden, Jessica E., et al.
Publicado: (2014)

The BET Family Member BRD4 Interacts with OCT4 and Regulates Pluripotency Gene Expression
por: Wu, Tao, et al.
Publicado: (2015)

BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion
por: Blee, Alexandra M., et al.
Publicado: (2016)

BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer
por: Hajmirza, Azadeh, et al.
Publicado: (2018)

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
por: Dai, Xiangpeng, et al.
Publicado: (2017)

Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
por: Wang, Wenyu, et al.
Publicado: (2021)

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer
por: Ding, Donglin, et al.
Publicado: (2022)

I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma
por: Guo, Ning-Hong, et al.
Publicado: (2019)

Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
por: Tiago, Manoela, et al.
Publicado: (2020)

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
por: Jia, Si-Qi, et al.
Publicado: (2022)

Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme
por: Ye, Yintao, et al.
Publicado: (2023)

The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2021)

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
por: Li, Zichong, et al.
Publicado: (2013)

BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5
por: Oien, Derek B., et al.
Publicado: (2023)

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
por: Brien, Gerard L, et al.
Publicado: (2018)

Oncogenes in high grade serous adenocarcinoma of the ovary
por: Manasa, Pacharla, et al.
Publicado: (2020)

BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity
por: Khoueiry, P., et al.
Publicado: (2019)

Brd/BET Proteins Influence the Genome-Wide Localization of the Kaposi’s Sarcoma-Associated Herpesvirus and Murine Gammaherpesvirus Major Latency Proteins
por: Lotke, Rishikesh, et al.
Publicado: (2020)

Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival
por: Lee, Minji, et al.
Publicado: (2018)

Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4
por: Hu, Xiangming, et al.
Publicado: (2017)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

Amplification of Cellular Oncogenes in Solid Tumors
por: Bagci, Ozkan, et al.
Publicado: (2015)

tBRD-1 Selectively Controls Gene Activity in the Drosophila Testis and Interacts with Two New Members of the Bromodomain and Extra-Terminal (BET) Family
por: Theofel, Ina, et al.
Publicado: (2014)

The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains
por: Alekseyenko, Artyom A., et al.
Publicado: (2015)

Abrogation of Brd4 cellular function contributes to the oncogenic mechanisms of translocation t(15;19)-associated carcinoma
por: Wang, Ranran, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4brjh60apknmuoqvof5q0cmt50